NeuroRx Company
NeuroRx develops NRX-101, an oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder.
Technology:
Others
Industry:
PharmTech
Headquarters:
Wilmington, Delaware, United States
Founded Date:
2015
Employees Number:
N/A
Funding Status:
N/A
Estimated Revenue:
$50M to $100M
Register and Claim Ownership